Cargando…
Isotopic Radiolabeling of Crizotinib with Fluorine-18 for In Vivo Pet Imaging
Crizotinib is a tyrosine kinase inhibitor approved for the treatment of non-small-cell lung cancer, but it is inefficient on brain metastases. Crizotinib is a substrate of the P-glycoprotein, and non-invasive nuclear imaging can be used to assess the brain penetration of crizotinib. Positron emissio...
Autores principales: | Sardana, Malvika, Breuil, Louise, Goutal, Sébastien, Goislard, Maud, Kondrashov, Mikhail, Marchal, Etienne, Besson, Florent L., Dugave, Christophe, Wrigley, Gail, Jonson, Anna C., Kuhnast, Bertrand, Schou, Magnus, Tournier, Nicolas, Elmore, Charles S., Caillé, Fabien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782192/ https://www.ncbi.nlm.nih.gov/pubmed/36559018 http://dx.doi.org/10.3390/ph15121568 |
Ejemplares similares
-
Isotopic Radiolabeling of the Antiretroviral Drug [(18)F]Dolutegravir for Pharmacokinetic PET Imaging
por: Tisseraud, Marion, et al.
Publicado: (2022) -
Comparison of the Blood–Brain Barrier Transport and Vulnerability to P-Glycoprotein-Mediated Drug–Drug Interaction of Domperidone versus Metoclopramide Assessed Using In Vitro Assay and PET Imaging
por: Breuil, Louise, et al.
Publicado: (2022) -
Visible-Light-Enabled
Aminocarbonylation of Unactivated
Alkyl Iodides with Stoichiometric Carbon Monoxide for Application
on Late-Stage Carbon Isotope Labeling
por: Sardana, Malvika, et al.
Publicado: (2019) -
Validation of a pharmacological imaging challenge using (11)C-buprenorphine and (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography to study the effects of buprenorphine to the rat brain
por: Soyer, Amélie, et al.
Publicado: (2023) -
Impact of Cytochrome Induction or Inhibition on the Plasma and Brain Kinetics of [(11)C]metoclopramide, a PET Probe for P-Glycoprotein Function at the Blood-Brain Barrier
por: Breuil, Louise, et al.
Publicado: (2022)